Pregabalin Capsule
Product Images NDC 60760-591

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-591). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-591 (Pregabalin 60760 591 60)

Pregabalin Capsules 100 mg label showing a quantity of 60 capsules. The label includes multiple listings of the drug name, strength, NDC 60760-591-60, and placeholder information for lot number and expiration date. The label indicates packaging by St. Mary's Medical Park Pharmacy, Oro Valley, AZ, and manufacturing by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. Storage instructions specify controlled room temperature between 15°-30°C (59°-86°F).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo. The graph illustrates the distribution of pain improvement across different Pregabalin dosages and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. It shows two lines representing Pregabalin 100 mg three times a day and Placebo, with Pregabalin consistently showing a higher percent of patients improved across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline for Pregabalin doses 300 mg, 150 mg, 75 mg taken twice a day versus placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percent of patients improved, with multiple dose response curves displayed.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows higher percentages of patient improvement for both Pregabalin doses compared to placebo across varying levels of pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

This chart shows the percent of patients improved versus percent improvement in pain from baseline in a study of pregabalin. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) from two clinical studies (Study E1 and Study E3) on Pregabalin. The graph compares different doses of Pregabalin (50 mg/day to 600 mg/day) and placebo, with responder rates increasing as dosage increases in both studies. Statistically significant differences versus placebo are indicated by asterisks.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph showing median percent seizure reduction from baseline versus dose (mg/day) for Pregabalin across four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. Data points indicate significant p-values for seizure reduction at increasing doses up to 600 mg/day, with placebo at zero dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 450 mg, and 800 mg daily compared to placebo. The graph shows treatment efficacy across various improvement thresholds, indicating trends in pain relief among different dosage groups and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR (long-term response) over 180 days between Pregabalin and placebo groups. The vertical axis ranges from 0% to 100%, and the horizontal axis represents days from 0 to 180. The Pregabalin group is shown with a solid line, maintaining a higher percentage of subjects without LTR over time compared to the placebo group, shown with a dashed line.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percentage of subjects improved from baseline to week 12 BOCF between Pregabalin and Placebo. The x-axis represents percent improvement ranges from 0 to 100, and the y-axis shows the percent of subjects improved, also from 0 to 100. The solid line represents Pregabalin, showing higher improvement percentages than the dashed line for Placebo across all ranges.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved from baseline to Week 16 by percent improvement using the 16 BOCF method. The graph shows two lines: one for Pregabalin and one for placebo, with the Pregabalin line consistently above the placebo line across percent improved values from 0 to 100.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel showing the formula for calculating creatinine clearance (CLcr), including adjustments for female patients. This appears to be part of clinical or pharmacokinetic information related to the dosage or use of Pregabalin capsules, 100 mg strength.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing the molecular arrangement including amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.